Financial Performance - The company's operating revenue for Q3 2023 reached ¥1,825,265,781.44, an increase of 2.03% compared to the same period last year[5] - Net profit attributable to shareholders was ¥122,161,215.07, reflecting a growth of 23.33% year-on-year[5] - Basic earnings per share for Q3 2023 was ¥0.18, up 20.00% year-on-year, while diluted earnings per share also increased by 28.57% to ¥0.18[5] - The net profit attributable to shareholders for the year-to-date period reached RMB 391,968,372.92, representing a year-on-year increase of 33.58%[27] - The operating revenue for the current period was RMB 6,497,534,830.57, compared to RMB 5,453,318,659.20 in the previous period, indicating a growth of approximately 19.06%[35] - The operating profit for the current period was RMB 446,870,220.76, up from RMB 338,081,275.06, marking an increase of about 32.3%[36] - The total comprehensive income for the current period was RMB 424,607,460.38, compared to RMB 281,032,140.69 in the previous period, indicating a significant increase of approximately 51%[36] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥76,245,167.69, a significant decline of 67.39% compared to the previous year, primarily due to prepayments from customers in the prior year[7] - Operating cash inflow for the current period was $5,530,713,748.91, an increase of 17.3% from $4,717,227,178.33 in the previous period[42] - Net cash flow from operating activities decreased to $76,245,167.69, down 67.4% from $233,819,696.10 in the previous period[42] - Cash outflow from financing activities increased to $1,041,449,917.28, compared to $728,570,872.30 in the previous period, reflecting a significant rise of 43%[43] - The company reported a net cash flow from financing activities of -$207,933,462.79, a decline from a positive cash flow of $376,795,259.04 in the previous period[43] - Cash and cash equivalents at the end of the period were $701,723,096.81, down from $1,049,450,512.26, a decrease of 33.2%[43] - Inventory decreased to $970,747,715.80 from $1,211,987,048.39, reflecting a reduction of 19.9%[52] - Total assets at the end of the reporting period were ¥7,921,817,083.48, down 4.15% from the end of the previous year[5] - The company’s total assets decreased from RMB 8,265,131,332.13 to RMB 7,921,817,083.48, a decline of about 4.2%[35] Shareholder and Equity Information - Shareholders' equity attributable to the parent company increased by 8.55% to ¥4,479,374,719.92 compared to the end of the previous year[5] - The total equity attributable to shareholders increased from RMB 4,126,460,390.95 to RMB 4,479,374,719.92, reflecting a growth of approximately 8.5%[35] - The company reported a total of 101,977 common shareholders at the end of the reporting period, with the largest shareholder holding 30.36% of the shares[8] Government Support and Investments - The company received government subsidies amounting to ¥6,357,208.63 during the reporting period, contributing positively to the financial results[5] - The company’s long-term equity investments increased slightly to $58,677,760.60 from $57,154,487.58, showing a growth of 2.7%[52] - The company’s cash inflow from investment activities was $20,162,660.04, up from $16,115,180.00, marking an increase of 25.4%[42] Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[5] - The company continues to focus on expanding its market presence and enhancing profitability through cost reduction and efficiency improvements[27]

山东新华制药股份有限公司（"本公司"）第十届董事会第十三次会议通知于二零二三年十 月十二日以邮件方式发出，会议于二零二三年十月二十七日在山东省淄博市高新区鲁泰大道 1 号公司会议室召开，应到会董事 8 名，实际参会董事 8 名。监事会成员和非董事的副总经理列 席了会议。会议由董事长贺同庆主持。会议的召开符合有关法律、法规、规章和公司章程的规 定。 会议主要审议并通过了以下议案： 一、审议通过了本公司二零二三年第三季度报告（见同日发布于《证券时报》及巨潮资讯 网公告）； 8 名董事赞成本议案，0 票反对，0 票弃权。 证券代码：000756 证券简称：新华制药 公告编号：2023-43 山东新华制药股份有限公司 第十届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 二、审议通过了关于修订公司治理相关文件的议案 特此公告 山东新华制药股份有限公司董事会 2023 年 10 月 27 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》及公司实际情况，为进一步 提高公司治理水平，修订了《董事会下属审核委员会的职权范围》及《独立董事工 ...

山东新华制药股份有限公司 董事会下属审核委员会的职权范围 （经公司于2023年10月27日召开的第十届董事会第十三次会议审议通过修订） 一般规定 成员 1 第一条：本公司须成立董事会下属审核委员会（"审核委员会"）。 第二条：审核委员会职权范围应遵守中华人民共和国（"中国"）公司法、（中国）上市公司治理准 则、关于在（中国）上市公司建立独立董事制度的指导意见、公司章程、香港联合交易所 有限公司证券上市规则 （"上市规则"）及其他相关规定。 第三条：该等职权范围中，"董事"指本公司董事会董事，"高级管理层"指总经理及副总经理、董 事会秘书及董事会根据总经理推荐而委任的其他高级管理层。 第四条：审核委员会成员由董事会从董事会的非执行董事中委任，大部分成员须为独立。根据香港联 合交易所上市规则第3.10(2)条规定，审核委员会至少由三名独立非执行董事（"独立非执 行董事"）组成，最少一名委员会成员须为具备适当专业资格或会计或相关财务管理专长的 独立非执行董事。 第五条：审核委员会召集人应为一名独立非执行董事，负责提供审核委员会的领导工作，并须由本公 司董事会委任。 第六条：本公司现时的核数公司（"审计机构"）不时的 ...

山东新华制药股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善山东新华制药股份有限公司("公司"或"本公司")法人治理结构，充分发挥独立 董事作用，促使独立董事忠实履行职责，更好地维护股东利益，促进公司规范运作，根据《中 华人民共和国公司法》、《中华人民共和国证券法》、《香港公司条例》、《上市公司治理准则》、《上 市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》（"《主板上市公司规范运作》"）、《山东新华制药股份有限公司章程》（"《公司章程》"） 和《香港联合交易所有限公司上市规则》等相关规定（"相关规定"），特制定本工作制度。 第二章 基本规定 1 第二条 本公司董事会成员中应当至少包括三分之一（或国内及香港证券监督机构不时要求的数目）独 立董事。 第三条 本公司独立董事（又称独立非执行董事）是指不在本公司担任除董事外的其他职务，并与本公 司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立客 观判断关系的董事。 第四条 独立董事对公司及全体股东负有诚信与勤勉义务。独立董事应当按国家相关法律、行政法规、 中国证券 ...

证券代码：000756 证券简称：新华制药 公告编号：2023-42 注册分类：化学药品4类 山东新华制药股份有限公司 关于取得阿哌沙班片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药品监 督管理局核准签发的阿哌沙班片（规格：2.5mg）（以下简称"本品"）《药品注册证书》。现将相 关情况公告如下： 一、基本情况 药品名称：阿哌沙班片 剂型：片剂 规格：2.5mg 药品分类：处方药 阿哌沙班片为口服抗凝剂，用于髋关节或膝关节择期置换术的成年患者，预防静脉血栓栓塞 事件（VTE）。由Bristol-Myers Squibb与Pfizer EEIG联合研发，2011年5月在欧盟上市，2013年 1月进入中国，2017年进入医保目录。阿哌沙班是一种可逆的、高选择性的直接Xa因子抑制剂， 属于新型口服抗凝药物。与维生素K抑制剂（如华法林）相比，阿哌沙班的安全性和耐受性好， 能有效地降低脑卒中和全身性栓塞的发生率，且不增加出血风险。据相关数据显示，阿哌沙班相 关制剂2021 ...

证券代码：000756 证券简称：新华制药 公告编号：2023-41 山东新华制药股份有限公司 关于 A 股股票交易异常波动公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、股票交易异常波动情况 山东新华制药股份有限公司（"公司"）2023 年 10 月 13 日、10 月 16 日 A 股股票连续两个 交易日收盘价格涨幅偏离值累计达到 20%，根据深圳证券交易所的有关规定，属于股票交易异常 波动的情况。 二、公司关注并核实的相关情况 2、近期公共传媒未报道可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、2023 年 8 月 25 日，公司披露了《2023 年半年度报告》。 5、2023 年 9 月 21 日，公司披露了《关于全资子公司药品通过仿制药一致性评价的公告》。 6、2023 年 10 月 11 日，公司披露了《关于非布司他获得化学原料药上市申请批准通知书的 公告 》。 公司未发现其他对公司股票交易价格可能产生较大影响的媒体报道或市场传闻，未发现其他 可能对公司股价产生 ...

证券代码：000756 证券简称：新华制药 公告编号：2023- 39 二、其他相关信息 2022年5月，高密公司向国家药品监督管理局药品审评中心（CDE）递交克拉霉素颗粒 （0.125g/5ml）一致性评价注册申报资料并获受理，2023年9月获得《药品补充申请批准通 知书》，审评结论为：经审查，本品视同通过仿制药质量和疗效一致性评价。高密公司目前 为本品首家通过仿制药质量和疗效一致性评价的企业。 克拉霉素颗粒适用于克拉霉素敏感菌所引起的下列感染：鼻咽感染：扁桃体炎、咽炎、 鼻窦炎；下呼吸道感染：急性支气管炎、慢性支气管炎急性发作和肺炎；皮肤软组织感染： 脓疱病、丹毒、毛囊炎、疖和伤口感染；急性中耳炎、肺炎支原体肺炎、沙眼衣原体引起的 尿道炎及宫颈炎等；也用于军团菌感染，或与其他药物联合用于鸟分枝杆菌感染、幽门螺杆 菌感染的治疗。 山东新华制药股份有限公司 关于全资子公司药品通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司之全资子公司新华制药（高密）有限公司("高密公 司")收到国家药品监督管理局核准签 ...

Financial Performance - The company achieved operating revenue of RMB 4,672,269 thousand, a year-on-year increase of 27.51%[43] - Net profit attributable to shareholders reached RMB 269,807 thousand, reflecting a growth of 38.80% compared to the previous year[43] - The company's net profit for the reporting period was RMB 26,173 thousand, a decrease of 13.82% compared to the same period last year, primarily due to severe market competition and insufficient demand leading to price declines[59] - The total profit for the period was RMB 331,945,812.26, representing a 41.06% increase year-on-year, showcasing improved profitability despite market challenges[82] - The total revenue for the first half of 2023 reached RMB 4,672,269,049.13, an increase from RMB 3,664,294,993.33 in the same period of 2022, representing a growth of approximately 27.5%[176] - The net profit for the first half of 2023 was RMB 275,680,432.27, compared to RMB 198,503,873.29 in the previous year, indicating a year-over-year increase of about 38.9%[176] - The operating profit for the first half of 2023 was RMB 333,956,283.28, up from RMB 237,764,708.38 in the same period last year, reflecting a growth of approximately 40.4%[176] - The total profit for the first half of 2023 was RMB 389,680,562.47, compared to RMB 155,353,236.44 in the same period of 2022, marking an increase of approximately 150%[189] Assets and Liabilities - The company reported a total long-term loan balance of RMB 804,985,266.90 at the end of the period, an increase from RMB 545,655,801.48 at the beginning of the year, representing a growth of approximately 47.3%[5] - The company’s total debt to capital ratio was 30.69% as of June 30, 2023[58] - The company's debt-to-asset ratio stood at 43.66%[88] - The total liabilities decreased to RMB 3,027,014,336.22 as of June 30, 2023, from RMB 3,401,905,893.46 at the end of 2022, a reduction of about 11%[174] - The total equity increased to RMB 3,862,924,360.67 as of June 30, 2023, compared to RMB 3,584,735,295.66 at the end of 2022, showing an increase of approximately 7.8%[174] Cash Flow and Liquidity - The company's cash and cash equivalents amounted to RMB 979,173,294.29, accounting for 12.13% of total assets[50] - The company's cash and cash equivalents at the end of the period amounted to RMB 979,173,294.29, a decrease of 15.5% from RMB 1,158,741,565.90 at the beginning of the year[171] - The total amount of restricted cash at the end of the period was RMB 124,873,547.56, down from RMB 147,977,218.39 at the beginning of the year, representing a decrease of 15.6%[171] - The company reported a significant decrease of 143.28% in the net increase of cash and cash equivalents, totaling RMB -156,464,600.78, highlighting liquidity challenges[83] Research and Development - Research and development expenses increased significantly as the company continued to enhance its technological innovation efforts[53] - The company’s research and development expenses in the first half of 2023 amounted to RMB 186,037,994.31, up from RMB 125,880,884.19 in the previous year, reflecting a growth of approximately 48%[189] - Research and development expenses increased by 39.72% to RMB 235,529,909.24 compared to the previous year, reflecting the company's commitment to innovation[82] - The company has established a comprehensive new drug research and development system and collaborates with over 50 domestic and international research institutions[91] Employee and Corporate Governance - The company’s total number of employees is 6,839, with 1,688 holding a university degree or higher[25] - The total number of employees as of June 30, 2023, was 6,839, with 3,864 in production roles and 904 in sales[41] - The company confirmed compliance with corporate governance codes and regulations as of June 30, 2023[169] - The company has appointed four independent non-executive directors, including one with financial management expertise, in accordance with listing rules[170] Environmental Compliance - The company has not faced any administrative penalties due to environmental issues during the reporting period, indicating compliance with environmental regulations[65] - The company has built three wastewater treatment facilities with a total capacity of 12,000 tons per day to ensure compliance with discharge standards[97] - The company has maintained its environmental management system since 1999, achieving multiple certifications from 2000 to 2022[102] - The company implemented a new RTO device with a capacity of 30,000 m³/h in 2022, which was officially put into operation in January 2023 to improve environmental conditions[133] Market and Product Development - The company launched 7 new products in the first half of the year, including 5 formulations and 1 active pharmaceutical ingredient, indicating a focus on product development[76] - The company has established long-term strategic partnerships with over 200 multinational corporations, including Bayer and GlaxoSmithKline, and is recognized as one of the top 15 enterprises in China to implement an internationalization strategy in pharmaceuticals[60] - The revenue from tablets, injections, and capsules was approximately RMB 2.09 billion, with a growth rate of 28.72%[85] - The revenue from direct sales was approximately RMB 1.88 billion, with a growth rate of 29.54%[85] - The revenue from the Americas region increased by 23.93%, reaching approximately RMB 405 million[85] Taxation - The company’s tax rate for its subsidiary, recognized as a high-tech enterprise, is 15% for the first half of 2023[13] - The effective corporate income tax rate for the company is currently 15% due to its recognition as a high-tech enterprise, which is under re-evaluation for 2023[185] - The company has subsidiaries benefiting from a 15% corporate income tax rate, including Shandong Xinhua Pharmaceutical Chemical Design Co., Ltd., recognized as a high-tech enterprise[186] Financial Management - The company reported a financial expense of RMB 1,688,843.56 in the first half of 2023, a decrease from RMB 16,651,235.73 in the previous year, indicating improved financial management[189] - The company’s other income for the first half of 2023 was RMB 11,102,958.72, down from RMB 15,323,110.21 in the same period of 2022, showing a decline of about 27%[189] Shareholder Matters - The board of directors has recommended not to distribute dividends for the first half of 2023 and will not increase capital from reserves[106] - The company has not engaged in any asset management or leasing arrangements with other companies during the reporting period[108] - There were no significant asset acquisitions or disposals during the reporting period[107]

2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 企业负责人：贺同庆 主管会计工作的负责人 ：侯宁 会计机构负责人：何晓洪 | 上市公司名称：山东新华制药股份有限公司 | | | | | | | | | | 单位：万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的关 联关系 | | 上市公司核算的会计科目 2023年初占用资金余额 | 2023年半年度占用累计发 生金额（不含利息） | 2023年半年度占 用资金的利息 | 2023年半年度偿还累 计发生金额 | 2023年6月末占用资金余额 | 占用形成原因 | 占用性质 | | 现大股东及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前大股东及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 总计 | | | | | | | | | | | | 其它关联资金 ...

证券代码：000756 证券简称：新华制药 公告编号： 2023-37 山东新华制药股份有限公司 关于获得苯甲酸阿格列汀片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"本公司"）收到国家药 品监督管理局核准签发的苯甲酸阿格列汀片（以下简称"该产品"）《药品注册证书》。现将 相关情况公告如下： 一、基本情况 药品名称：苯甲酸阿格列汀片 剂型：片剂 受理号：CYHS2200419国、CYHS2200420国 药品批准文号：国药准字H20234021、国药准字H20234022 证书编号：2023S01252、2023S01253 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。 二、其他相关信息 规格：25mg、12.5mg 药品分类：处方药 注册分类：化学药品4类 申请人：山东新华制药股份有限公司 申请事项：药品注册（境内生产） 山东新华制药股份有限公司董事会 2023年8月11日 2022年3月，新华制药向国家药 ...